Bill Meagher

Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.

Recent Articles By The Author

Beware the Flood of Reg-Lite Listed Companies

Beware the Flood of Reg-Lite Listed Companies

The first company that need tell investors little about itself has hit the market, and is expected open the floodgates for more.

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.

FDA deals blow to Endo over Opana ER Pain Med

FDA deals blow to Endo over Opana ER Pain Med

An FDA advisory committee has found that risks of Endo International's pain drug Opana ER now overshadow the drug's benefits.

Otsuka Pharmaceutical Acquires Neurovance, ADHD Therapy

Otsuka Pharmaceutical Acquires Neurovance, ADHD Therapy

Otsuka could wind up paying as much as $250 million for venture-backed Neurovance as the target moves its flagship candidate into phase 3 trial.

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

Perrigo also said it will review its API business, which provides differentiated active pharmaceutical ingredients and finished dosage forms for the branded and generic industries.